IGF::OT::IGF OTHER FUNCTIONS PHASE I, TOPIC 309, LABEL-FREE MULTIVARIATE CANCER DIAGNOSIS

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: N43CO120071
Agency Tracking Number: N43CO120071
Amount: $199,767.00
Phase: Phase I
Program: SBIR
Awards Year: 2012
Solicitation Year: 2012
Solicitation Topic Code: NCI
Solicitation Number: N/A
Small Business Information
AMBERGEN, INC, 313 PLEASANT ST, WATERTOWN, MA, -
DUNS: 878574755
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 CHRISTOPHER SEARS
 (617) 923-9990
 CSEARS@AMBERGEN.COM
Business Contact
 CHRISTOPHER SEARS
Phone: (617) 923-9990
Email: CSEARS@AMBERGEN.COM
Research Institution
 Stub
Abstract
Significant progress has been made recently in developing multi-analyte prognostic cancer signatures based on gene expression profiling (GEP). However, current industry-standard RT-PCR platforms require substantial amounts of clinical samples, such as multiple FFPE tumor sections. These large sample requirements preclude less invasive biopsy sampling techniques, such as fine needle aspiration. In addition, few patients and/or signatures can be assayed simultaneously on standard RT-PCR platforms due to limited spatial and analytical capacity, thereby driving up assay cost. To meet these challenges, a new RT-PCR platform for measuring multi-analyte prognostic cancer signatures will be evaluated. Based on WaferGen s SmartChip technology, this platform willenable template requirements to be reduced by 1/16th of conventional amounts while dramatically increasing the number of patients and signatures that may be run simultaneously. This innovation will greatly reduce costs and make such prognostic assays moreaccessible to cancer patients. In phase I, the new approach will be evaluated utilizing AmberGen s 12-gene colorectal cancer prognostic signature, which achieved 95% sensitivity and 99% specificity to predict recurrence in a blinded study. A custom SmartChip will be designed to enable the CRC recurrence signature to be measured simultaneously for 48 patients, and is expected to achieve similar levels of accuracy.

* Information listed above is at the time of submission. *

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government